Abstract: Association between the angiotensinogen gene (M235T) and pre-eclampsia has been confirmed in recent studies. Pre-eclampsia is a complication of pregnancy characterized by increased vascular resistance, higher blood pressure, proteinuria and oedema that appear in the second and third trimester of pregnancy. This study aimed at investigating the relationship between M235T gene polymorphism and pregnant women with different forms of pre-eclampsia. One hundred and fifteen pre-eclamptic women and 100 normal control group were recruited and evaluated for the frequency of M235T mutation using polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP). A positive association was found between maternal age over 35 years (OR= 6.67; CI: 2.09-23.59), previous family history of hypertension (OR= 3.01; CI: 1.18-7.66), previous pre-eclampsia (OR= 7.44; CI: 2.47-22.42), history of reproductive losses (OR = 53.98; CI: 3.23-90.88), fetal anomalies (OR= 8.4; CI: 1.06-180.33), and pre-eclampsia. The frequency of heterozygous carriers of M235T mutation in preeclampsia (19.1%) was higher than that in control (14%) but the difference was statistically non-significant. Also, the frequency of M235T mutation was higher in mild pre-eclampsia women (63.6%) compared to women with severe pre-eclampsia (36.4%), however this was statistically non-significant. This study revealed that the frequency of M235T mutation was higher within women with mild pre-eclampsia.
INTRODUCTION
Pre-eclampsia is a disorder associated with pregnancy that consists of hypertension and proteinuria and manifests often after 20 th weeks of gestation. (1) It is a heterogenous disorder which complicates 5-7% of all pregnancy usually primigravida and in women with preexisting hypertension or vascular diseases . (2) Although the etiology of pre-eclampsia remains unclear, it has been suggested that abnormal placentation and endothelial cell dysfunction are key features of pathogenesis of pre-eclampsia. (3) It was observed that preeclampsia is associated with increased risks of placental abruptia, acute renal failure, cerebrovascular and cardiovascular complications, disseminated intravascular coagulation, and maternal death. (4) The fetus may be affected by growth retardation and about 20% cases die either in utero or as a result of prematurity. (5) Pre-eclampsia can be classified as mild or severe. Severe pre-eclampsia is characterized by hypertension greater than (160/110 mmHg) and the presence of significant proteinuria. It is sometimes associated with oliguria, cerebral or visual disturbances, pulmonary oedema, or cyanosis. In mild pre-eclampsia, hypertension and proteinuria are present, but not to these extreme levels, and the patients has no evidence of other organ dysfunctions. (6) Pre-eclampsia appears to have a genetic component and pedigree analysis suggests that it may be inherited as a single-gene disorder. (7) Candidate genes that determine blood pressure variation include those whose products have a direct role in vascular biology, such as components of the renin-angiotensin system. (8) The importance of the rennin-angiotensin system for maintenance of normal cardiovascular homeostasis and its participation in the pathophysiology of pre-eclampsia is well established. The plasma-renin activity is high and the level of angiotensinogen may be also increased, suggesting a possible role of angiotensiogen in pre-eclampsia. (9) The M235T angiotensinogen gene T235 allele represents the mutant allele and M235 allele represents the wild type. (10) The aim of this study was to investigate the relationship between M235T gene polymorphism and pregnant women with different forms of pre-eclampsia. 
MATERIAL and METHODS

Dip stick urine analysis testing for
protein.
Laboratory investigations
including: CBC, urea, creatinine, fasting blood sugar, serum uric acid and liver enzymes. The detection for this mutation was done as follows:
1-DNA amplification
In order to amplify the 165 bp fragment that contains the M235T polymorphism, the first set of second exon primers described by Russ et al., (12) and Jeunemaitre et al., (13) were used. The forward primer was:
5CAGGGTGCTGTCCACACTGGACC
CC-3, and the reverse primer was:
Genomic DNA (500 ng) was amplified in 
2-Enzymatic Digestion
Enzymatic 
3-Electrophoresis
The digestion products were separated by electrophoresis on 3% agarose gel, (stained with 2 µL of 10 mg/ml ethidium bromide solution), for 30 minutes at 125V. 
Interpretation of results:-
RESULTS
This study included 115 women with pre-eclampsia and 100 normal controls.
The risk factors among patients and controls are shown in 
DISCUSSION
Pre-eclampsia is a multifactorial complication of pregnancy and it remains one of the most important causes of maternal and fetal mortality, and morbidity in developed countries. (14) Sometimes, it progresses to eclampsia in which potentially life-threatening seizures result. Thus, there is critical need for strategies to predict, prevent, and improve management of this disorder that safely prolongs gestation and would be a major advance in prenatal care. (15) Maternal age greater than 35 years is one of the maternal specific risk factors for pre-eclampsia. (16) (2) found that most of the studied women were below 35 years. These Myatt and Miodovnick, (1999) (18) reported that the risk of pre-eclampsia is 4 times higher the relative risk-being the daughter or a sister of a women who has had pre-eclampsia. In the present study, family history of pre-eclampsia had a significant higher risk for pre-eclampsia (OR = 3.01, CI: 2.47-22.42).
Pre-eclampsia is associated with higher risk of intra-uterine growth retardation (IUGR), abortion, intrauterine fetal deaths (IUFD), and congenital fetal anomalies. (5, 19) Significant frequencies of congenital fetal anomalies (4.3%) and reproductive losses (20%) (abortion, IUFD and still births) were observed in the present study among the pre-eclamptic women.
This may be attributed to the fact that pre-eclampsia is associated with high perinatal morbidity and mortality rates as a result of iatrogenic prematurity. (20) Although the etiology is unclear, a strong genetic component have been suggested. (2) Pre-eclampsia is associated with a common molecular variant of angiotensinogen (ATG) gene (Met 235 → Thr 235). (21) Several studies, (7, 10, 22, 23) found that a molecular variant of angiotensinogen (M235T) in Japanese, Romenians, Caucasians, and (24) and Guo et al., (1997) . (25) However, different results were obtained by Ward et al., (1993) (22) and Moses et al., (2000) . (23) This discrepancy might be attributed to the criteria used to diagnose pre-eclampsia .
The present study revealed that 22 (19.1%) women with pre-eclampsia were heterozygous affected (MT) and 17 (14.8%) were homozygous affected (TT) for this mutation. Lucia et al., (2002) (10) reported in their study that the frequency of heterozygous women for the mutation (64.28%) was higher than that of the homozygous (14.28%) ones.
CONCLUSION
The frequency of M235T mutation was higher in women with mild preeclampsia and there was no significant association between the mutation and pre-eclamptic patients.
This is a preliminary study and more hypertensive and normotensive pregnant women need to be comparatively studied in order to improve statistical significance and to confirm that the presence of M235T angiotensinogen gene polymorphism can be considered as a risk factor in pre-eclamptic women.  = Reference category. S = Significant association. NS = Non-significant association. 
